Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Parkinsonian disorders

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    24 result(s) found for: Parkinsonian disorders. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2008-002578-36 Sponsor Protocol Number: 2008/0817 Start Date*: 2008-09-10
    Sponsor Name:CHRU de LILLE
    Full Title: Etude d’efficacité et d’acceptabilité d’un traitement cholinergique dans l’apathie parkinsonienne “Cholinergic treatment in Parkinsonian Apathy: ChoPA - I”
    Medical condition: Parkinsonian Apathy without dementia and depression in spite of dopaminergic treatment
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2012-001218-40 Sponsor Protocol Number: SC12-02 Start Date*: 2012-05-21
    Sponsor Name:FONDAZIONE SANTA LUCIA
    Full Title: EFFICACY OF ROTIGOTINE ON GAIT PERFORMANCE OF PARKINSONIAN PATIENTS
    Medical condition: Patients suffering for Idiopathic Parkinson’s Disease. H&Y stage > or = 2 with un-satisfactory control by on-going pharmacological therapy (Levodopa, COMT & MAO-inhibitors), characterised by an in...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10056242 Parkinsonian gait PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-002216-25 Sponsor Protocol Number: PDT409 Start Date*: 2006-06-26
    Sponsor Name:Amersham Health, S.A. (filial de GE Healthcare Ltd)
    Full Title: Ensayo en fase 4 multicéntrico, aleatorizado, abierto y comparativo para evaluar las modificaciones en el manejo clínico después de una tomografía con DaTSCAN en sujetos con parkinsonismo clínicame...
    Medical condition: The subjects included in this trial will have clinically uncertain parkinsonism in a general neurologist setting.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) IT (Completed) DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-000364-21 Sponsor Protocol Number: PI1102031 Start Date*: 2012-11-13
    Sponsor Name:Fundació Clínic per a la Recerca Biomédica
    Full Title: FDDNP-PET FOR IN VIVO DIAGNOSIS OF TAUOPATHY IN UNCLASSIFIABLE PARKINSONISM
    Medical condition: Atypical Parkinsonism
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10034010 Parkinsonism PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-004145-16 Sponsor Protocol Number: Z7219K01 Start Date*: 2019-07-24
    Sponsor Name:Zambon SpA
    Full Title: A 12-weeks, multicentre, randomized, double-blind, placebo-controlled, exploratory, pilot study to evaluate the safety and efficacy of safinamide 200 mg once daily, as add-on therapy, in patients w...
    Medical condition: Parkinsonian variant of Multiple System Atrophy
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10064060 Multiple system atrophy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2009-010193-38 Sponsor Protocol Number: IPX066-B08-05 Start Date*: 2009-06-02
    Sponsor Name:IMPAX Pharmaceuticals a Division of IMPAX Laboratories, Inc.
    Full Title: A Placebo-Controlled Study to Evaluate the Safety and Efficacy of IPX066 in Subjects with Parkinson's Disease
    Medical condition: Idiopathic Parkinson's disease (paralysis agitans)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10061536 Parkinson's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Completed) EE (Completed) LV (Completed)
    Trial results: View results
    EudraCT Number: 2020-000122-26 Sponsor Protocol Number: 125591 Start Date*: 2020-05-11
    Sponsor Name:University College London (UCL)
    Full Title: A Phase IIa, open label, single-site, 48 week randomised controlled trial evaluating the safety and efficacy of Exenatide once-weekly in the treatment of patients with Multiple System Atrophy
    Medical condition: Multiple System Atrophy
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10064060 Multiple system atrophy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2011-001092-39 Sponsor Protocol Number: CAQW051A2209 Start Date*: 2011-06-29
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A multi-centre, randomized, double-blind, placebo-controlled, parallel-group, multiple oral dose study to assess the efficacy, safety and tolerability of AQW051 in reducing L-dopa induced dyskinesi...
    Medical condition: L-dopa induced dyskinesias in Parkinson’s patients with moderate to severe L-dopa induced dyskinesias
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10034005 Parkinson's disease and parkinsonism HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-000361-11 Sponsor Protocol Number: RD639/24201 Start Date*: 2006-06-23
    Sponsor Name:Fujimoto Pharmaceutical Corporation
    Full Title: A Proof of Concept Study to Determine the Minimum Effective Dose and to Assess the Efficacy and Safety of Subcutaneous Injections of FPFS-1169 in Parkinson's Disease Patients
    Medical condition: Treatment of Parkinson's Disease
    Disease: Version SOC Term Classification Code Term Level
    8.0 10029205
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2015-000373-13 Sponsor Protocol Number: AMBS-ELTO-201 Start Date*: 2015-08-18
    Sponsor Name:Amarantus BioScience Holdings, Inc.
    Full Title: Phase 2, multicenter, randomized, double-blind, placebo-controlled, four-period cross-over, dose-range finding study to evaluate the safety, tolerability and efficacy of Eltoprazine in the treatmen...
    Medical condition: Parkinson’s disease levodopa induced dyskinesia (PD-LID)
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029205 - Nervous system disorders 10061536 Parkinson's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Temporarily Halted)
    Trial results: (No results available)
    EudraCT Number: 2011-002073-30 Sponsor Protocol Number: CAFQ056A2222 Start Date*: 2011-11-16
    Sponsor Name:Novartis Farmaceutica, S.A.
    Full Title: 12-week, double-blind, placebo-controlled, fixed-dose, multicenter study to evaluate the efficacy and safety of AFQ056 in reducing moderate to severe L-dopa induced dyskinesias in patients with Par...
    Medical condition: L-dopa induced dyskinesias in patients with Parkinson?s disease
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029205 - Nervous system disorders 10013929 Dyskinesias and movement disorders NEC HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2009-015161-31 Sponsor Protocol Number: P04938 Start Date*: 2010-08-17
    Sponsor Name:Schering-Plough Research Institute, a division of Schering Corporation
    Full Title: A Phase 3, 12-Week, Double-Blind, Double-Dummy, Placebo- and Active-Controlled Efficacy and Safety Study of Preladenant in Subjects With Moderate to Severe Parkinson’s Disease (Phase 3; Protocol No...
    Medical condition: Parkinson's disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10061536 Parkinson's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) GB (Completed) CZ (Completed) FR (Completed) NL (Completed) ES (Completed) AT (Completed) DE (Completed) IT (Completed) SE (Completed) PT (Completed) BG (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2021-000854-24 Sponsor Protocol Number: VE-CIP2001/2021 Start Date*: 2021-12-21
    Sponsor Name:ALFASIGMA S.P.A.
    Full Title: Velusetrag for the treatment of Chronic Intestinal Pseudo-Obstruction (CIPO). A multicenter double-blind, placebo-controlled, cross-over, multiple (n=1) trial.
    Medical condition: Chronic intestinal pseudo-obstruction (CIPO) is a rare, severe condition characterized by an impairment of coordinated propulsive activity in the intestinal tract resulting in a clinical picture si...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10017947 - Gastrointestinal disorders 10017947 Gastrointestinal disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) BE (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-002678-29 Sponsor Protocol Number: ANAVEX2-73-PDD-EP-001 Start Date*: 2019-12-05
    Sponsor Name:Anavex Life Sciences Corp.
    Full Title: Open Label Extension Study for Patients with Parkinson’s Disease with Dementia Previously Enrolled in ANAVEX2-73-PDD-001 Study for Continued Safety Assessment
    Medical condition: Cognition in Parkinson’s Disease with Dementia
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10067889 Dementia with Lewy bodies PT
    20.0 10029205 - Nervous system disorders 10061536 Parkinson's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-002074-23 Sponsor Protocol Number: CAFQ056A2223 Start Date*: 2012-03-20
    Sponsor Name:Novartis Pharma Services AG
    Full Title: 13-week, double-blind, placebo-controlled, fixed-dose, multicenter study to evaluate the efficacy and safety of modified release AFQ056 in reducing moderate to severe L-dopa induced dyskinesias in ...
    Medical condition: L-dopa induced dyskinesias in patients with Parkinson's disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10013929 Dyskinesias and movement disorders NEC HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) ES (Completed) IT (Completed) SK (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2010-020112-11 Sponsor Protocol Number: P07037 Start Date*: 2011-06-29
    Sponsor Name:Schering-Plough Research Institute, a division of Schering Corporation
    Full Title: A Phase 3, 12-Week, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Preladenant in Subjects with Moderate to Severe Parkinson’s Disease. (Phase 3; Protocol No. P07037)
    Medical condition: Parkinson's disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10061536 Parkinson's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Completed) LV (Completed)
    Trial results: View results
    EudraCT Number: 2011-003053-25 Sponsor Protocol Number: 1466 Start Date*: 2012-06-18
    Sponsor Name:Research and Enterprise Department
    Full Title: A randomised, double blind, placebo controlled trial to evaluate the effect of Rivastigmine on gait in people with Parkinson’s disease who have fallen.
    Medical condition: Parkinson's disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10061536 Parkinson's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2022-001542-38 Sponsor Protocol Number: ANVS-22001 Start Date*: 2023-01-09
    Sponsor Name:Annovis Bio, Inc.
    Full Title: A 6-month prospective, randomized, double-blind, placebo-controlled clinical trial investigating the efficacy, safety, and tolerability of two different doses of buntanetap or placebo in patients w...
    Medical condition: Parkinson’s disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) IT (Completed) PL (Completed) ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-002600-24 Sponsor Protocol Number: Z7219L02 Start Date*: 2015-11-03
    Sponsor Name:Zambon S.P.A.
    Full Title: A TWO YEAR, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY TO EVALUATE THE LONG TERM EFFICACY AND SAFETY OF SAFINAMIDE 100 MG, ONCE DAILY, AS ADD ON THERAPY, IN IDIOPATHIC PARKINSO...
    Medical condition: Idiopathic Parkinson's Disease
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029205 - Nervous system disorders 10061536 Parkinson's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) SE (Prematurely Ended) AT (Prematurely Ended) ES (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-000135-14 Sponsor Protocol Number: PXT-CL17-001 Start Date*: 2017-05-26
    Sponsor Name:Prexton Therapeutics B.V.
    Full Title: A Multi-centre, Double-blind, Randomised, Placebo-controlled, Parallel-arm Phase IIa Trial to Evaluate the Efficacy, Safety and Tolerability of 28-Day Oral Treatment with PXT002331 (foliglurax) in ...
    Medical condition: Parkinson’s Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10061536 Parkinson's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) DE (Completed) GB (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 31 14:30:01 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA